A central composite design-based targeted quercetin nanoliposomal formulation: Optimization and cytotoxic studies on MCF-7 breast cancer cell lines.

Breast cancer Central composite design Cytotoxic Nanoliposomes Quercetin

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Sep 2024
Historique:
received: 21 05 2024
revised: 02 09 2024
accepted: 03 09 2024
medline: 19 9 2024
pubmed: 19 9 2024
entrez: 19 9 2024
Statut: epublish

Résumé

This study aimed to enhance the efficacy of quercetin (QT) by formulating it into a liposomal drug delivery system utilizing the concept of central composite design. The drug:lipid ratio, cholesterol concentration, and sonication time were selected as independent variables in the study. The vesicle and percentage entrapment efficiency were selected as the dependent variables. Quercetin nanoliposomes (QT-NLs) were prepared via a combination of ethanol injection and thin film hydration. The vesicle size and entrapment efficiency of all formulations were within the ranges of 100 nm and >80 %, respectively. The zeta potential value indicated the stability of the optimized formulation. The contour plots were used to select the desired batch range. SEM studies revealed an imperfect crystalline morphology without any unwanted agglomeration. MTT assays on VERO cell lines indicated the safety of the developed formulation. MTT assays of MCF-7 cells revealed IC

Identifiants

pubmed: 39296160
doi: 10.1016/j.heliyon.2024.e37430
pii: S2405-8440(24)13461-5
pmc: PMC11409131
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e37430

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

E Bhargav (E)

Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh, India.

Nawaz Mohammed (N)

Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh, India.

Udit Narayan Singh (UN)

Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh, India.

P Ramalingam (P)

Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Bihar, India.

Ranadheer Reddy Challa (RR)

Formulation and Development, Quotient Sciences, 3080 McCann Farm Dr, Garnet Valley, PA, USA.

Bhaskar Vallamkonda (B)

Somerset Therapeutics Limited, New Jersey, USA.

Sheikh F Ahmad (SF)

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh-11451, Saudi Arabia.

Prasanth Dsnbk (P)

School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS), Jadcherla, Hyderabad, India.

Praveen Kumar Pasala (PK)

Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh, India.

Mithun Rudrapal (M)

Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research, Guntur, Andhra Pradesh, India.

Classifications MeSH